Latest quarterly report‼️ Stemlim S-high! SanBio S-high! Going strong‼️
The peptide drug derived from the regenerative inducer therapeutic called Redasemtide (HMGB11) has announced that the second phase trial conducted at Shionogi in patients with acute ischemic stroke achieved the primary endpoints. In addition, safety as a secondary endpoint was confirmed, indicating tolerability. Moving forward, preparations will be made at Shionogi to transition to a global phase 3 clinical trial.
× ![]()